SpectRx' cervical cancer detector outperforms Pap
This article was originally published in Clinica
Executive Summary
An early clinical trial has shown that SpectRx' noninvasive cervical cancer detection device can detect 17% more high-grade precancerous lesions than thin-layer Pap tests and 28% more than traditional smear tests.